ABT enters the final stretch of summer with a rare alignment of signals: a fresh analyst upgrade, a stock up 12% over the past month, and options traders at their most bullish in a year.
The most telling move of the week came from Wolfe Research, which upgraded ABT to Outperform from Peer Perform on August 13 and set a $130 price target. That upgrade arrived into a stock already riding post-earnings momentum. Following Q2 results in mid-July — where the stock jumped more than 12% in a single session — the bulk of the Street lifted targets in unison. JP Morgan raised to $120 from $110, Evercore ISI moved to $120 from $112, and BTIG pushed its target to $134. The consensus message is clear: seventeen buy ratings against six holds, with a mean target of $119.40 against a current price of $112.68. The Street still sees roughly 6% upside from here, though UBS trimmed its target to $125 from $135 in late July — a lone note of caution in an otherwise constructive chorus.
Options positioning reinforces the bullish tilt. The put/call ratio has dropped to 0.63, its lowest level of the past 52 weeks, running nearly 1.6 standard deviations below its 20-day average of 0.67. That is the most call-heavy options skew has shown all year, reflecting investors leaning into upside rather than hedging against downside. The lending market adds nothing to worry about: short interest is just 1.3% of the free float, down nearly 6% on the week, and availability is effectively unlimited — there is far more stock available to borrow than anyone is using. Borrowing costs remain negligible at 0.39%. This is not a short-seller story.
Valuation has re-rated alongside the price. The P/E has expanded by roughly 1.7 points over the past 30 days to just under 19x, and price-to-book has risen by 0.13 turns to 3.9x. Neither is stretched for a large-cap medtech name with the growth profile ABT is currently demonstrating, but the multiple expansion does narrow the margin of safety for new buyers. The dividend score ranks in the 98th percentile, and the analyst recommendation differential ranks at the 97th — both pointing to a name well-supported by income and growth investors alike. Factor scores on momentum and short positioning (80th percentile on utilization rank) round out a picture of a stock where the path of least resistance has been firmly upward.
Institutional holders have been quietly adding. BlackRock increased its position by nearly 6.9 million shares in the most recently reported period, bringing its stake to 8.8% of shares. State Street and Capital Research also added incrementally. The insider picture is more mixed — an Executive VP sold just over 5,800 shares at $109.83 on August 11 — but the net 90-day insider flow is modestly positive at roughly $721,000, driven by director and CFO purchases earlier in the spring at prices around $87-$93. Those buyers are comfortably in the money.
The next formal test is Q3 earnings, scheduled for October 14. The last two quarterly prints each produced double-digit single-day moves to the upside — a pattern that sets an elevated bar for October, and makes the degree to which Q3 results can sustain the narrative around diagnostics and emerging-market demand the key question to watch between now and then.
See the live data behind this article on ORTEX.
Open ABT on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
